IMAP is pleased to announce that Degroof Petercam acted as Joint Global Coordinator in CARMAT’s €40.5 million capital increase. The fundraising included €36.5m for institutional and strategic investors and €4.1m for retail investors (via the PrimaryBid platform).
CARMAT is the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative to people suffering from end-stage biventricular heart failure.
The Company is planning to use the funds to ensure the continuity of its activities, and notably to support the restart of the production of its Aeson® artificial heart and ensure the resumption – scheduled for October 2022 – of its implants, both from a commercial standpoint and within the framework of its clinical trials.
Degroof Petercam acted as joint Global Coordinator, joint Lead Manager and joint Bookrunner. Bertrand Dufournier, Ivan Huet, Nicolas Heurtebize and Samuel Benarosch were involved from the Corporate Finance team in France and Olivier de Vos from the Corporate Finance team in Belgium, as well as Gert Potvlieghe and Raymond de Wolff on the ECM/Syndication side.
This transaction highlights the strength of Degroof Petercam’s franchise in the healthcare sector, the seamless combination of its Corporate Finance and ECM resources and its placement reach with international institutional investors.
Degroof Petercam is IMAP’s exclusive corporate finance partner in France and Belgium.